In a meta-analysis, CEUS had higher accuracy for differentiating benign and malignant lesions than conventional US (94% versus 83%); however, further evaluation of the clinical use of CEUS is needed [15]. aVanderbilt University Medical Center, Nashville, Tennessee. bPanel Chair, University of Michigan, Ann Arbor, Michigan. cThe George Washington University Medical Center, Washington, District of Columbia; Commission on Nuclear Medicine and Molecular Imaging. dVanderbilt University Medical Center, Nashville, Tennessee; O-RADS Committee. eMedstar Georgetown University Hospital, Washington, District of Columbia. fBeth Israel Deaconess Medical Center, Boston, Massachusetts. gUniversity of California San Diego, San Diego, California; American College of Obstetricians and Gynecologists. hCleveland Clinic, Cleveland, Ohio. iHospital of the University of Pennsylvania, Philadelphia, Pennsylvania. jAscension St. Vincent's, Jacksonville, Florida and University of South Florida, Tampa, Florida; Gynecologic oncologist. kMayo Clinic Arizona, Phoenix, Arizona; IF Committee. lDepartment of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. mYale University School of Medicine, New Haven, Connecticut; Committee on Emergency Radiology-GSER. nMayo Clinic, Rochester, Minnesota. oUniversity of California San Diego, San Diego, California; Commission on Radiation Oncology. pSpecialty Chair, New York University Medical Center, New York, New York. Reprint requests to: publications@acr.org OR Discussion of Procedures by Variant Variant 1: Adult patient assigned female at birth. Clinically suspected adnexal mass, no acute symptoms. Premenopausal or postmenopausal. Initial imaging. CT Pelvis With IV Contrast CT pelvis with intravenous (IV) contrast is typically not useful for the initial workup and characterization of adnexal masses due to suboptimal delineation of soft tissue in the adnexal region.
Clinically Suspected Adnexal Mass No Acute Symptoms. In a meta-analysis, CEUS had higher accuracy for differentiating benign and malignant lesions than conventional US (94% versus 83%); however, further evaluation of the clinical use of CEUS is needed [15]. aVanderbilt University Medical Center, Nashville, Tennessee. bPanel Chair, University of Michigan, Ann Arbor, Michigan. cThe George Washington University Medical Center, Washington, District of Columbia; Commission on Nuclear Medicine and Molecular Imaging. dVanderbilt University Medical Center, Nashville, Tennessee; O-RADS Committee. eMedstar Georgetown University Hospital, Washington, District of Columbia. fBeth Israel Deaconess Medical Center, Boston, Massachusetts. gUniversity of California San Diego, San Diego, California; American College of Obstetricians and Gynecologists. hCleveland Clinic, Cleveland, Ohio. iHospital of the University of Pennsylvania, Philadelphia, Pennsylvania. jAscension St. Vincent's, Jacksonville, Florida and University of South Florida, Tampa, Florida; Gynecologic oncologist. kMayo Clinic Arizona, Phoenix, Arizona; IF Committee. lDepartment of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. mYale University School of Medicine, New Haven, Connecticut; Committee on Emergency Radiology-GSER. nMayo Clinic, Rochester, Minnesota. oUniversity of California San Diego, San Diego, California; Commission on Radiation Oncology. pSpecialty Chair, New York University Medical Center, New York, New York. Reprint requests to: publications@acr.org OR Discussion of Procedures by Variant Variant 1: Adult patient assigned female at birth. Clinically suspected adnexal mass, no acute symptoms. Premenopausal or postmenopausal. Initial imaging. CT Pelvis With IV Contrast CT pelvis with intravenous (IV) contrast is typically not useful for the initial workup and characterization of adnexal masses due to suboptimal delineation of soft tissue in the adnexal region.